Download
fimmu-12-640093.pdf 1,51MB
WeightNameValue
1000 Titel
  • Two Different Antibody-Dependent Enhancement (ADE) Risks for SARS-CoV-2 Antibodies
1000 Autor/in
  1. Ricke, Darrell O. |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-02-24
1000 Erschienen in
1000 Quellenangabe
  • 12:640093
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.3389/fimmu.2021.640093 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7943455/ |
1000 Ergänzendes Material
  • https://www.frontiersin.org/articles/10.3389/fimmu.2021.640093/full#h12 |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • COVID-19 (SARS-CoV-2) disease severity and stages varies from asymptomatic, mild flu-like symptoms, moderate, severe, critical, and chronic disease. COVID-19 disease progression include lymphopenia, elevated proinflammatory cytokines and chemokines, accumulation of macrophages and neutrophils in lungs, immune dysregulation, cytokine storms, acute respiratory distress syndrome (ARDS), etc. Development of vaccines to severe acute respiratory syndrome (SARS), Middle East Respiratory Syndrome coronavirus (MERS-CoV), and other coronavirus has been difficult to create due to vaccine induced enhanced disease responses in animal models. Multiple betacoronaviruses including SARS-CoV-2 and SARS-CoV-1 expand cellular tropism by infecting some phagocytic cells (immature macrophages and dendritic cells) via antibody bound Fc receptor uptake of virus. Antibody-dependent enhancement (ADE) may be involved in the clinical observation of increased severity of symptoms associated with early high levels of SARS-CoV-2 antibodies in patients. Infants with multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19 may also have ADE caused by maternally acquired SARS-CoV-2 antibodies bound to mast cells. ADE risks associated with SARS-CoV-2 has implications for COVID-19 and MIS-C treatments, B-cell vaccines, SARS-CoV-2 antibody therapy, and convalescent plasma therapy for patients. SARS-CoV-2 antibodies bound to mast cells may be involved in MIS-C and multisystem inflammatory syndrome in adults (MIS-A) following initial COVID-19 infection. SARS-CoV-2 antibodies bound to Fc receptors on macrophages and mast cells may represent two different mechanisms for ADE in patients. These two different ADE risks have possible implications for SARS-CoV-2 B-cell vaccines for subsets of populations based on age, cross-reactive antibodies, variabilities in antibody levels over time, and pregnancy. These models place increased emphasis on the importance of developing safe SARS-CoV-2 T cell vaccines that are not dependent upon antibodies.
1000 Sacherschließung
gnd 1206347392 COVID-19
lokal antibody dependent enhancement
lokal ADE
lokal MIS-C
lokal multisystem inflammatory syndrome
lokal SARS-CoV-2
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/Umlja2UsIERhcnJlbGwgTy4=
1000 Label
1000 Förderer
  1. Office of the Under Secretary of Defense |
1000 Fördernummer
  1. FA8702-15-D-0001
1000 Förderprogramm
  1. Research and Engineering under Air Force Contract
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Office of the Under Secretary of Defense |
    1000 Förderprogramm Research and Engineering under Air Force Contract
    1000 Fördernummer FA8702-15-D-0001
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6428050.rdf
1000 Erstellt am 2021-06-08T17:17:55.024+0200
1000 Erstellt von 218
1000 beschreibt frl:6428050
1000 Bearbeitet von 25
1000 Zuletzt bearbeitet 2021-06-29T13:57:52.998+0200
1000 Objekt bearb. Tue Jun 29 13:57:33 CEST 2021
1000 Vgl. frl:6428050
1000 Oai Id
  1. oai:frl.publisso.de:frl:6428050 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source